These results also provide a foundation for the design and selection of next-generation high-avidity antibodies that are selective for oligomers formed by other proteins involved in protein misfolding disorders, including α-synuclein in Parkinson’s disease, superoxide dismutase 1 in amyotrophic lateral sclerosis and tau in tauopathies. Here, MAPT is linked to proteostasis deficiencies.